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Infant formulae are the only alternatives
to breast milk for infants who are unable
to continue breastfeeding through the 
first year of life. They aim to provide
formula-fed infants with the same
structural and functional benefits
observed in breastfed infants. To achieve
this, bioactive nutrients have been added
to infant formulae in recent years: long-
chain polyunsaturated fatty acids for
neurodevelopment; probiotics and pre-
biotics for local gastrointestinal defence;
and nucleotides for promoting the
immune response. Changes in protein
quantity and quality allow infant
formulae to achieve a balance between
providing the correct plasma amino acid
profile and reducing the protein intake,
which could prevent obesity in later life.
Hydrolysed proteins may help prevent
atopic disorders. Many short-term trials
have been published but long-term follow-
up data are needed in infants who have
been fed the newer infant formulae, to
fully understand the role of bioactive
nutrients.
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Introduction
FROM NUTRIENT COMPOSITION TO
NUTRIENT FUNCTION 
Breast milk is required for optimum short-
and long-term growth in infancy and the
importance of this has been recognized by
the World Health Organization (WHO). The
lower incidence of infectious diseases in
breastfed babies has been shown in both
developing and industrialized countries,1
and recent studies have also demonstrated
that breastfeeding is associated with a higher
intelligence quotient (IQ) and a lower
prevalence of obesity, during both infancy
and adolescence.2,3 The effect of breast-
feeding on the prevention of atopy and
allergic symptoms in the paediatric
population has not been well defined.4 The
WHO suggests that exclusive breastfeeding
should be carried out for the first 6 months of
life in all infants, in both developing and
industrialized countries. In situations where
a mother is unable to breastfeed, infant
formula should provide a safe and
nutritionally adequate human milk substitute.
The incidence of breastfeeding is increasing
considerably in the developed world
countries:5 for example, recent epidemio-
logical research has demonstrated the rising
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rate in Italy.6 Nevertheless, the number of
European mothers who breastfeed beyond 
4 – 6 months is well below optimum levels.5
In addition, Italian mothers often switch
very rapidly during the first year of life to
either modified or unmodified whole cows’
milk.7 Within this context, the first
educational goal should be to explain the
functional advantages of prolonged breast-
feeding to mothers. If, for whatever reason,
human milk becomes unavailable to an
infant, then during the first 6 months of life
a new-generation cows’ milk formula that is
closer to the gold standard of human milk
should be used, followed by an appropriate
follow-on formula. 
Cows’ milk formulae that are currently
available should be evaluated to see whether
they:
(i) Provide the best alternative to human
milk for infants who cannot be breastfed
during the first 6 months of life;
(ii) Can substitute for human milk with the
aim of approaching the structural and
functional effects observed with breast-
feeding.
At present, the nutrient composition and
daily variability of human milk cannot be
reproduced in formulae feeds. The origins of
the main nutrients (e.g. proteins, lipids and
carbohydrates), which are derived from non-
human milk sources and biosynthetic
processes, dictate that the quantities and the
proportions of nutrients found in cows’ milk
formulae do not exactly reflect those present
in human milk.8 As a consequence, the
protein and lipid intakes differ between
breastfeeding and formula feeding,8,9 and
bacterial intestinal flora – which is
considered the best biomarker for dietetic
carbohydrate concentrations – is very
different in breastfed and formula-fed
infants.10 The absorption and bioavailability
of the main micronutrients (e.g. calcium and
iron) seem to depend on the macronutrient
composition of infant formulae.11 Recent
developments in infant formulae have
therefore been targeted towards reproducing
the functional effects, rather than the
quantitative composition, of human milk.
The term ‘functional nutrient’ has become
part of the scientific language and several
new nutrients have been added to (or are
being studied with a view to being added to)
infant formulae. These include:
(i) Long-chain polyunsaturated fatty acids
(LCPUFA), for cerebral tissue composition
and for neurological development;
(ii) Probiotics and prebiotics, for intestinal
bacterial flora and local immune
defence at a gastrointestinal level;
(iii) Nucleotides, to promote the immune
response;
(iv) Possible quantitative and qualitative
protein composition modifications, to
balance the plasma amino acid profile
(this is particularly significant for neuro-
transmitter function in the early stages
of cerebral development). Reducing the
protein intake in the early years of life is
recognized as an important factor for the
prevention of excessive weight gain and
obesity;
(v) Hydrolysed protein introduction for the
prevention of atopy.12
These nutritional developments have
enabled dietetic product manufacturers to
conduct research, through which they have
established the optimum proportions of
different functional nutrients in infant
formulae. Consequently, new-generation
cows’ milk formulae can provide functionally
positive dynamic effects when selected
ingredients are added to different types of
milk. This is in contrast to earlier-generation
infant formulae in which the balance of
nutrients was undertaken in a purely
‘quantitative’ manner. In practice, the
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concept that infant formula is a substitute
for cows’ milk has been replaced by a new
concept which suggests that infant formula
is a real alternative to human milk, when
this is not available to the infant.
Points to be considered when
evaluating infant formulae
Nutrients added to infant formulae may
have purely nutritional functions or they
may have defence, immune, pro-anabolic
and neurotrophic roles, so serving as
functional compounds. Therefore, during the
evaluation of the nutritional identity of
different cows’ milk formulae our attention
will focus on these components:
(i) Protein, glucid and lipid quantity and
quality;
(ii) Immunoregulatory factors including
indigestible carbohydrates (prebiotics),
acidifying molecules, lactic bacteria
(probiotics) and nucleotides.
PROTEIN QUANTITY AND QUALITY 
Compared with breastfed infants, formula-fed
infants consume 65 – 70% more protein.13 A
different plasma amino acid profile has been
associated with formula-fed infants13,14
together with a different glucose-insulin
axis.15,16 A lower rate of body mass growth 
in the 6 – 12-month period seems to be
associated with breastfeeding compared with
formula feeding, although the differences
disappear in the second year of life.9,17,18
Breastfed babies have a lower prevalence of
excess weight and obesity in infancy, which
varies in a manner that is dependent upon
the duration of breastfeeding.19 The ‘protein
hypothesis’ represents an interesting
biological explanation for the development
of excessive weight gain and obesity, and an
ongoing European trial aims to verify this
point.20 As a consequence of these findings,
the ideal composition of any infant formula
that aims to be a breast-milk substitute
should result in a similar plasma amino acid
profile. Many studies have shown that
formula-fed infants have significantly
higher plasma levels of numerous amino
acids and urea than breastfed infants.13
Casein-predominant formula (whey:casein
ratio of 18:82) produces higher plasma levels
of tyrosine and phenylalanine and lower
plasma levels of tryptophan compared with
whey-predominant formula (whey:casein
ratio of 60:40);14 while hyperthreoninaemia
is a well-known phenomenon in infants
receiving a whey-predominant formula.13
Picone et al.21 have demonstrated that a milk
formula with a whey:casein ratio of 50:50
produces an amino acid profile that is closer
to that of human milk compared with the
more commonly used formulae containing
whey: casein ratios of 60:40 or 20:80.13
Despite feeding infants with a cows’ milk
formula containing a reduced total
quantitative protein level and a whey:casein
ratio of 50:50, it has still not been possible to
produce a plasma amino acid profile that
can be superimposed on to that of the
breastfed infant.21 The proteins in infant
formulae are not species-specific;
consequently, they cannot be reduced below
certain limits as the levels of some essential
amino acids, in particular tryptophan, could
fall below essential levels. 
At present, two approaches can be used to
reduce the protein concentration of infant
formula without altering the plasma amino
acid profile: 
(i) Removal of the whey protein glycomacro-
peptide, with a consequent reduction in
the plasma threonine concentration
(which is usually increased in infants fed
with a whey-predominant formula);22
(ii) Formula enrichment with α-lactoal-
bumin, a tryptophan-rich protein which
limits the amount of other amino acids
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in a low-protein infant formula.23 In the
neonate, tryptophan and its metabolites
are essential for optimal cerebral
development, including the correct
development of the hunger, satiety and
sleep-wake rhythm regulation systems.23
Human milk contains elevated con-
centrations of tryptophan, the precursor
of serotonin and melatonin, compared
with other neutral amino acids, and
tryptophan transport across the
blood–brain barrier is optimal.23 In
contrast, cows’ milk formula provides
lower tryptophan levels with higher
concentrations of neutral amino acids.
This seems to be associated with the
lower concentrations of α-lactoalbumin
in cows’ milk compared with human
milk. Infants fed with a low-protein
infant formulae enriched with 
α-lactoalbumin had serum amino acid
profiles that were more similar to those
of breastfed infants.24 New methods of
fractionating whey protein, which
remove glycomacropeptide that is rich 
in threonine and poor in tryptophan,
and increase the tryptophan-rich 
α-lactoalbumin proportion, may allow
formula-fed infants to achieve a plasma
amino acid profile similar to that of
breastfed infants.
PROBIOTICS AND PREBIOTICS    
Probiotics (micro-organisms that have
beneficial effects on the host) and prebiotics
(indigestible probiotic substrates) have
become familiar terms in the clinical and
scientific communities. Probiotics and
prebiotics are mainly recognized for their
ability to modulate the intestinal flora.
Whether probiotics – either ingested directly
or stimulated by the ingestion of prebiotics –
act independently on the immune system by
local or systemic means, and the
mechanisms involved in such actions, are
not fully understood. Bifidobacteria and
Lactobacillus represent the main beneficial
strains of organisms that are used in probiotic
supplementation, but the optimum quality
and strains of probiotics are not absolutely
certain. Documented evidence of the positive
effects on the host organism exists for 
L. rhamnosus GG, L. reuteri, L. acidophilus,
Bifidobacterium species and Saccharomyces
boulardi.25 Their probiotic biological activities
might be explained by their adhesion to
enterocytes, which could potentially inhibit
the attachment of enteropathogenic strains
of bacteria. The production of bacteriocines
and short-chain fatty acids (mainly butyric
acid) could also inhibit replication of
pathogenic bacteria.25
Probiotics have been employed with
success in the therapy and prevention of
some forms of gastroenteritis.25,26 A medium-
term study has demonstrated that some
probiotic strains of bacteria may be able to
modify allergic inflammatory processes, and
their effects continue after ingestion of the
probiotic has stopped.27
Prebiotics, which mainly consist of
indigestible oligosaccharides, are ingredients
added to foods that can positively influence
the host organism by stimulating the growth
and/or activity of bacterial strains already
present in the host organism, particularly in
the colon. Prebiotics are used to modify
microflora composition by stimulating the
colonization of the gut by commensals that
provide recognized benefits to the host
organism. There is evidence that prebiotics
increase the quantities of bifidobacteria and
Lactobacillus species and decrease Escherichia
coli and Clostridia species quantities in the 
gut.28 On an industrial level, the main
substances that can selectively influence 
and be advantageous to the intestinal
microflora are lactulose, vegetable-derived
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fructo-oligosaccharides (FOS) and synthetic
galacto-oligosaccharides (GOS). Recent
studies have evaluated the addition of
prebiotic oligosaccharides consisting of 90%
GOS and 10% FOS (up to 0.8 g/dl) to infant
formula. This type of infant formula
supplementation was associated with a dose-
dependent elimination of bifidobacteria and
Lactobacillus in the stools.29,30 Prebiotics have
also been associated with regulating
frequency of evacuation and softer stool
consistency.29,30 All of the prebiotic-
supplemented infant formulae were well
tolerated and no side-effects have been
linked to their use.28 The ESPGHAN
Committee on Nutrition has published two
reports on the use of probiotics and
prebiotics in dietetic products for infancy
(Table 1).28,31
The use of a separate fermentation
process for proteins is a third possible
mechanism of infant formula supple-
mentation. This produces active metabolites
during milk fermentation that stimulate the
host organism’s defences in a way analogous
to those observed with probiotic and pre-
biotic infant formula supplementation.32,33
LONG-CHAIN POLYUNSATURATED
FATTY ACIDS FOR NEUROLOGICAL
DEVELOPMENT  
The observation that breastfed babies have
better neurological development compared
with formula-fed infants34 has led to
hypotheses suggesting a possible role for
LCPUFA, particularly arachidonic acid (AA,
20:4n-6) and docosahexaenoic acid (DHA,
22:6n-3), which are derived from linoleic
acid (LA, 18:2n-6) and α-linolenic acid (ALA,
18:3n-3), respectively (Fig. 1).
TABLE 1: 
The ESPGHAN Committee on Nutrition: conclusions and recommendations on the
inclusion of probiotics and prebiotics in infant dietetic products28,31
Data are still limited on the safety and long-term effects of probiotic preparations added to infant
and follow-on formulae and dietetic products for infancy. Some data suggest a short-term benefit
of some probiotic strains in neonates and small infants with infectious diarrhoea
Only use bacterial strains for which the identity and genetic stability have been demonstrated by
culture and molecular methods
Probiotic-containing infant formulae should only be marketed after a careful evaluation of the
benefits and safety. Fewer controls are needed for follow-on formulae because the infant has
already been exposed to environmental organisms and has developed a mature immune response
The evidence that some probiotic-based preparations show relative benefits should be
recognized on the basis of diarrhoea severity, effective prevention of diarrhoeal episodes, and
short to medium-term preventive effects on atopic eczema
Available data on the use of prebiotics in infant dietetic products are still limited. General
recommendations on the use of prebiotic molecules with preventive or therapeutic effects during
infancy cannot therefore be given
Some prebiotics can increase the total number of bifidobacteria in the stools and they can make
the stools ‘soft’ 
Negative effects of the mixture of oligosaccharides used in dietetic products for infancy have not
been documented 
Future studies should define the type and dosage of oligosaccharides with a presumed prebiotic
activity, optimal dosages and length of the administration, relative safety aspects of
administration, and the potential short- and long-term effects
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The hypothesis that LCPUFA play a role 
in the performance of the nervous system 
is supported by experimental, anatomo-
pathological and clinical data.35 In the 1980s,
animal studies demonstrated a possible role
for dietary LCPUFA in improving the neuro-
physiological response, in particular the
visual processes.36 Several studies have
demonstrated beneficial effects associated with
ALA administration, which increases the
availability of substrate for DHA synthesis.37
A study of sudden infant death syndrome
demonstrated that breastfed infants had a
significantly greater amount of DHA in their
cerebral cortex grey matter compared with
formula-fed infants.38 These findings have
focused attention on the role of DHA in the
early stages of neurodevelopment, and
clinical studies are now evaluating the 
long-term effects of DHA on IQ.39
Even very low birth-weight infants can
synthesize LCPUFA from their precursor
molecules, but the fundamental problem is
whether they can produce an adequate
quantity of LCPUFA to allow optimum
neurological development.40 How the roles of
AA and DHA in infancy are defined in terms
of whether they are essential, conditionally
essential or semi-essential fatty acids is not
yet known, although this issue has been
thoroughly investigated using meta-
analyses.41,42 Numerous organizations and
international committees have considered
the definition of LCPUFA function in
infancy.43 While the dietary supply of
LCPUFA is always associated with a
biochemical response (i.e. higher plasma
levels of LCPUFA), doubts have been raised
about the functional meaning of these
increased levels in terms of their impact 
on neurological development. While a
systematic literature analysis confirms the
benefits of using dietary LCPUFA for
premature infants, the situation in term
FIGURE 1: Synthesis of long-chain polyunsaturated fatty acids and their essential fatty
acid precursors
18:2n-6 (linoleic acid, LA) 18:3n-3 (α-linolenic acid, ALA)
∆6 desaturases ∆6 desaturases
18:3n-6 (γ-linolenic acid, GLA) 18:4n-3 (stearidonic acid)
elongases
20:3n-6 (di-homo-γ-linolenic acid)
∆5 desaturases
20:4n-6 (arachidonic acid, AA) 20:5n-3 (eicosapentaenoic acid, EPA)
elongases (2)
∆6 desaturases
peroxisomal β-oxidation
22:6n-3 (docosahexaenoic acid, DHA)
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infants remains inconclusive as there are
several diverse interpretations of the
available data, in addition to a lack of
medium- and long-term data.44 According to
leading researchers, cows’ milk formulae for
term infants should contain at least 0.2% of
the total fatty acids as DHA and 0.35% as
AA, while cows’ milk formulae for pre-term
infants should contain at least 0.35% DHA
and 0.40% AA.43
Systematic reviews and current recom-
mendations confirm the lack of adverse effects
associated with dietetic LCPUFA supple-
mentation.41 – 43 A meta-analysis of data
from several clinical trials demonstrated that
LCPUFA administration, either alone or in
combination with AA, was not associated
with reduced development of stature or
weight parameters in term infants.45
NUCLEOTIDES
Human milk contains a much higher
concentration of nucleotides than cows’
milk.46 Nucleotides can be extracted and
added to infant formula, and their potential
for stimulating the immune response has
resulted in an ever-greater number of
nucleotide-supplemented infant formulae
becoming available.46
Nucleotides and their associated
metabolites play key roles in numerous
biological processes.47 They can be
synthesized by the organism and are
therefore not considered essential nutrients,
but some studies have demonstrated that
nucleotides ingested as part of the diet can
bring benefits; as a result their role in
human nutrition has been defined as
‘conditionally essential’.47 These nutrients
can become essential as soon as the
endogenous levels become insufficient to
sustain normal function, even if their
absence from the diet does not constitute a
classic malnutrition syndrome. Most of the
dietary-ingested nucleotides are rapidly
metabolized and excreted, although some
are incorporated into the tissues, particularly
in early life and during conditions of
malnutrition.47 In the case of limited
nucleotide intake, rapid growth or some
physiological states, dietary nucleotide
intake can support ex novo synthesis and
optimize the maturation of rapidly growing
tissues, such as the gastrointestinal epithelium
and immune system cells.47 Breastfed infants
receive nucleotides from human milk in the
form of nucleic acids, nucleosides,
nucleotides and associated metabolites.48
Nucleotides ingested with the diet have been
associated with an increase in the host
defences at the gastrointestinal and immune
system levels.47 Infants who receive a cows’
milk formula supplemented with nucleotides
experienced a reduced risk of diarrhoeal
episodes,49 a greater antibody response
following vaccination against Haemophilus
influenzae type B,50 and a greater natural
killer cell activity compared with infants
given a non-supplemented formula.51
The hypothesis that nucleotides are
conditionally essential nutrients remains to
be confirmed, in particular with regard 
to pre-term infants, intrauterine growth
retardation, intestinal illness and states of
malnutrition. As no negative effects have
been reported for nucleotide-supplemented
infant formulae, these compounds are
considered safe to be used at concentrations
similar to those found in human milk.
Further studies are required to define the
precise biological role of nucleotides in
human milk, and to establish which benefits
are associated with the nucleotide supple-
mentation of infant formulae and at what
concentrations they should be added.
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PROTEIN HYDROLYSATES AND
ALLERGY PREVENTION
At least temporarily, 30% of the paediatric
population is estimated to be affected by
atopic symptoms.52 The intensity of allergic
reactions, their prevalence, the discomfort
caused by them and the costs involved mean
that allergies are of major clinical interest;
consequently, the modification of infant
formulae and infant foods in order to make
them less likely to be associated with the
future development of allergic symptoms is
an area that requires further study. The role
of breastfeeding in the development of
allergies remains controversial.53,54 Breast-
feeding for 4 – 6 months reduced allergic
symptoms in high-risk infants (i.e. mother
and/or father affected by allergy) compared
with infants fed with a cows’ milk formula,
but recent findings indicate that the
concentration of specific defence factors in
human milk can affect the development of
the allergic response.55 Extensively hydro-
lysed proteins derived from cows’ milk, in
which most of the nitrogen is in the form of
free amino acids and peptides < 1500 kDa,
have been used in formulae for > 50 years for
infants with cows’ milk protein allergy.56 The
use of extensively hydrolysed proteins to
prevent allergy development when human
milk is unavailable remains difficult because
of the palatability, costs and long-term
nutritional effects of these formulae. In 1985,
the first partially hydrolysed formula was
introduced to the market as a less expensive
and more palatable alternative to standard
hydrolysed infant formulae, and one which
might offer a preventive, rather than
therapeutic, effect.56 The European Union
has accepted that infant formulae can be
labelled ‘hypoallergenic’ (HA) if clinical
studies have confirmed that a formula can
prevent allergic symptoms. In 1998, a meta-
analysis reviewed 15 prospective studies that
measured the effect of feeding a partially
hydrolysed formula for at least 3 months to
infants at risk of allergy. The study looked at
the development of allergic symptoms
between 6 and 60 months of life52 and
showed that at 6 and 12 months of age, the
proportion of infants fed with HA formula
who developed allergic symptoms was 
one-third and one-quarter of the respective
proportions of infants receiving standard
cows’ milk formula.52 No significant 
differences were found when comparing the
infants fed with HA formula and breastfed
infants.52 According to the recent German
Nutrition Intervention Trial, breastfed, HA
formula-fed, or extensively hydrolysed
formula-fed high-risk infants showed 
lower incidences of allergic manifestations
compared with high-risk infants fed with 
a standard infant formula.57 In particular,
allergic manifestations were particularly
prevented by the use of extensively
hydrolysed products, while atopic dermatitis
was reduced by either type of hydrolysed
formula.57 A Swiss cohort study showed that
feeding infants with HA formula for up to 4
months of life resulted in a normal growth
pattern and an improvement in general
health status compared with infants
receiving a standard infant milk formula.58
From these studies there is a consensus
view that the extensively hydrolysed infant
formulae have less allergic potential when
used as alternatives to human milk, but that
greater nutritional safety has only been
demonstrated by hydrolysed formulae that
have a low degree of hydrolysis.59,60
A review of the composition
of different infant formulae
This review will now discuss the composition
of a variety of infant formulae that are
available in Italy from several manufacturers.
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Table 2 lists the composition of 27 infant
formulae in detail.
PROTEIN
Quantity
The following innovations have been used in
specific milks to overcome the potential
problems associated with protein content,
weight gain and obesity without leading to
suboptimal amino acid levels (as discussed
earlier in this article):
(i) Techniques that increase concentrations
of α-lactoalbumin after its isolation from
the casein band (formulae 2, 8, 8A 
and 9);
(ii) Isolation of glycomacropeptide, which
results in a reduced threonine
concentration: threonine is usually
found in excess in whey-protein
predominant formulae.
Partial protein hydrolysis
Infant formulae 3B and 8A contain
hydrolysed proteins that could prevent both
colic and the development of atopy.
LIPIDS
Absorption
Different amounts of β-palmitate, which is
present in human milk, have been added to
infant formulae 3B, 8A, 10, 10A and 13A, to
ensure a greater absorption of lipids and
prevent the precipitation of lipids in the form
of calcium soaps. The amount of β-palmitate
added to infant formulae should always be
precisely stated as the percentage of the total
palmitate content: this can be the source of
important functional differences between
infant formulae.
Quality
At present, all of the commercially available
formulae contain LA and ALA at a ratio that
has been modified to be ≤ 10:1, respectively.
In some infant formulae (1, 3, 12, 12A, 13
and 13A), variable amounts of AA and DHA
have been added. In formula 10A, γ-linolenic
acid instead of AA, together with DHA, has
been added.
CARBOHYDRATES 
Lactose is the only carbohydrate present in
formulae 6, 6A, 7, 11, 12 and 13A, although
this is associated with greater fermentability
than other carbohydrates. In all other 
infant formulae, lactose, maltodextrins,
polysaccharides (digestible and indigestible)
and/or starches have been added:
(i) Maltodextrins (digestible sugars that
probably ensure less fermentability):
formulae 1, 1A, 2, 2B, 4, 4A, 4B, 5, 7A, 8,
8A, 9, 10, 10A, 12A and 13;
(ii) Digestible polysaccharides (probably
have an anti-fermentation effect):
formulae 3B and 3C;
(iii) Starch or amylopectin (possibly have an
anti-reflux effect): formulae 2A, 2B, 3B,
7A, 8A, 10A and 12A;
(iv) Indigestible polysaccharides (bifidogenic
effects, prebiotics): formula 1 (GOS only),
formulae 3, 3A and 3B (GOS:FOS ratio
9:1), formula 8A (GOS only), and
formula 10 (FOS only). In formulae 4A
and 4B indigestible polysaccharides were
present as fermentation products.
BIOLOGICAL ACIDIFICATION 
The acidification of formulae 4A, 4B and 8A,
which aims to prevent local intestinal
infections, is obtained using different pro-
cedures. In some formulae (2B and 7A),
lactic bacteria have been included to
stimulate the successive development of
acidification.
NUCLEOTIDES
In light of the possible positive effect of
nucleotides on the immune system, some
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infant formulae have been supplemented
with nucleotides at doses below those found
in human milk (formulae 2, 4A, 5, 8, 8A, 9,
10, 11, 12 and 13).
Do infant formulae with
bioactive nutrients work?
Considerable research by Italian groups over
the past 10 years has evaluated the possible
effects of functional nutrients added to
infant formulae. Most studies have
considered the neurodevelopmental and
metabolic effects of LCPUFA,61 – 66 and the
effects of prebiotics and probiotics on
intestinal flora, bowel habits and infections
(such as necrotizing enterocolitis in
infants).67 – 70 Adding LCPUFA to infant
formulae has increased neurodevelopmental
performance to levels closer to those
achieved in breastfed infants.61,71 Prebiotics
have produced intestinal effects similar to
those observed with breastfeeding.28 The
addition of probiotics has not produced
favourable effects, however.31 In general, the
considerable efforts made by infant formula
and food manufacturers have greatly
improved the diets of those who, for several
reasons, have not been fed with their
mother’s own breast milk. 
Conclusion
The different types of infant formulae now
available aim to provide nutritional
alternatives for infants who are unable to
receive breast milk. Infant formulae aim to
produce the same structural and functional
nutritional effects observed in breastfed
infants, which are particularly important
during the early months of life when human
milk should be the only nutrient source.
Long-term follow-up data are required for
infants fed with the new types of infant
formulae. Such data will enable us to assess
their possible effects on neurobehavioural
performance, prevention of excess weight
gain and obesity, and the development of
immunoallergic symptoms beyond the
favourable findings that have come from
short-term studies.
In addition to the qualitative improvement
in infant formula composition which aims to
provide nutrients of measurable functional
value to formula-fed infants, other new
Explanation of terms and formulae used in Table 2, which describes the composition of
different infant milk formulae that are used as alternatives to human breast milk in Italy
*Enriched with Bifidobacterium lactis, fermented with Lactobacillus helveticus and Streptococcus thermophilus.
**Fermented with Streptococcus thermophilus and Bifidobacterium breve.
***Pre-treated acidified milk with Streptococcus thermophilus.
†β-palmitate.
††Ingredients from biological agriculture.
LA, linoleic acid; ALA, α-linolenic acid; AA, arachidonic acid; DHA, docosahexaenoic acid; GLA, γ-linolenic acid;
GOS, galacto-oligosaccharides; FOS, fructo-oligosaccharides.
Formula 1 = Humana 1 (Humana); formula 1A = Humana Plus (Humana); formula 2 = Nidina 1PE (Nestlé);
formula 2A = Nidina Confort 1 (Nestlé); formula 2B = Pelargon 1* (Nestlé); formula 3 = Aptamil 1 
(Milupa-Numico); formula 3A = Nutrilon 1 (Nutricia-Numico); formula 3B = Conformil 1 (Milupa-Numico); 
formula 3C = Milumil 1 (Milupa-Numico); formula 4 = Mellin1 (Mellin); formula 4A = Mellin 1 Progress**
(Mellin); formula 4B = Pantolac 1** (Mellin); formula 5 = Bebilac 1 (Sicura srl); formula 6 = Miltina 1 (Milte); 
formula 6A = Bio-miltina 1 (Milte); formula 7 = Nativa 1 (Guigoz); formula 7A = Nativa 1 Bifidus* (Guigoz);
formula 8 = Plasmon 1 (Plasmon); formula 8A = Lenilac 1*** (Plasmon); formula 9 = Vivena 1†† (Dieterba);
formula 10 = Formulat 1 (Dicofarm); formula 10A = Formulat 1 Pregel (Dicofarm); formula 11 = Similac
Formula Plus 1 (Abbott); formula 12 = Enfamil Premium 1 (Mead Johnson); formula 12A = Enfamil Pregel 
Lipil 1 (Mead Johnson); formula 13 = Blemil Plus forte 1 (Ordesa); formula 13A = Blemil Plus AS 1 (Ordesa).
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